Sign up to save your podcasts
Or
Share Mesalamine Dosage and Fecal Calprotectin in Patients With Quiescent Ulcerative Colitis
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Mesalamine Dosage and Fecal Calprotectin in Patients With Quiescent Ulcerative Colitis
A study in the November issue of CGH investigated whether increasing doses of mesalamine reduces concentrations of fecal calprotectin in patients with quiescent ulcerative colitis. Dr. Kuemmerle speaks to author Dr. James D. Lewis.
View all episodes
By AGAA study in the November issue of CGH investigated whether increasing doses of mesalamine reduces concentrations of fecal calprotectin in patients with quiescent ulcerative colitis. Dr. Kuemmerle speaks to author Dr. James D. Lewis.